



Hua Medicine

FY2021 Annual Results Announcement Webinar Invitation

Hua Medicine (2552.HK) cordially invites you or your representative to attend the online webinar in relations to the Company's FY2021 annual results, which will be held 8:00 AM GMT+8, 17 March 2022 (Thursday).

During the webinar, management will provide a review of the Company's business and financial performance, as well as address the questions surrounding the full-year financial results in 2021.

Details of the webinar are as follows:

Language:	English
Date:	17 March 2022 (Thursday)
Time:	Login starts: 7:45AM GMT+8 Meeting starts: 8:00AM GMT+8
Duration:	Approx. 45 mins (including Q&A session)
Management:	Dr. Li Chen, CEO, Founder, and Chief Scientific Officer Mr. George Lin, Chief Financial Officer and Executive Vice President
RSVP:	Registration Link: https://icaasia.zoom.us/webinar/register/WN_brRTyTDdQGu5BI0KfeDFSsw (Please register via the above link no later than 16 March 2022) 1. Registration is invite-only and is subject to company approval. 2. Upon successful registration, a personalized meeting link will be sent to the registered email. Please use the link to access the meeting.
Q&A:	If you have any questions, please send them to huamedicine@icaasia.com before 16 March 2022 (Wednesday). Company management will address the received questions during the Q&A session. Other questions could also be raised during the Q&A session subject to the meeting time.

**If you are intended to attend the Chinese session (9:00AM GMT+8, 17 March), please send an email to huamedicine@icaasia.com for registration. Meeting details will be provided upon confirmation.*

About Hua Medicine

Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates ultimate global resources to explore breakthrough technologies and products, and accelerate global innovation in diabetes care. Targeted on glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug, restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around world.